Key Takeaways

  • The UK market is still undervalued, despite the FTSE 100’s record climb.
  • Basic materials stocks are the most attractively valued out of all UK sectors.
  • UK housing stocks such as Persimmon screen as undervalued.

With many global stock markets, including the UK, hitting new records recently, finding quality stocks at a decent price has become a challenge for investors.

The Morningstar UK Index has returned 18.3% year to date in pounds, marking its best run since 2009, ahead of the US market and level pegging with stocks in the eurozone.

While this gain has made the UK market’s price/fair value less attractive than it was three years ago, domestic stocks are still screening as undervalued overall.

And looking at the relative attractiveness of stock market valuations across regions makes a compelling case for investing in the UK: of the US, UK, and European stock markets, the UK is the most discounted of the three.

“We find the UK equity market more attractive than the US market—especially because US valuations are particularly steep at the moment,” says Nicolò Bragazza, associate portfolio manager at Morningstar.

Are UK Stocks Attractively Priced?

The UK’s FTSE 100 index hit another record high at the start of Q4, making 2025’s gains the best since 2009 so far. Financials and defense stocks have driven the UK market gains. After a volatile first half of the year, because of the tariff selloff, US markets have regained momentum and found a new leg upwards as the Nvidia-driven AI boom continues.

What’s the Outlook for UK Stocks in Q4?

The recovery in share prices, especially in the US, is visible in the chart above, with a sharp drop in April followed by a sharp, but sustained recovery.

This move has left US stocks as a whole screening just above 1, meaning they are, on aggregate, overvalued.

UK stocks, however, currently trade at a more attractive price/fair value ratio of 0.92. Though this discount is smaller than it was this time a year ago, it allows investors more of a “margin of safety”, a key tenet of value investing.

“The UK is cheaper than the US, but it’s also cheap relative to the rest of Europe,” says Morningstar chief European market strategist Michael Field.

“The broader European index is trading at 0.94. The main takeaway from this is that it’s all about relative discounts these days. With the US trading at a slight premium, the UK represents good value at the margin.”

Which UK Stock Sectors Look Cheap?

Within the UK stock market, basic materials, real estate, and healthcare companies are screening as more undervalued than the wider market.

Out of 11 Morningstar stock sectors, basic materials stocks are the most attractively valued at 0.82 price/fair value, with UK healthcare and real estate close behind at 0.85.

As the table below shows, these three sectors are the fourth, seventh and ninth-best performing sectors of 11 peers since the start of the year. Basic materials stocks have returned 14.12%, with healthcare lagging behind on 7.13%, and real estate on 2.70%.

In the basic materials sector, mining giant Glencore GLEN appears among the most attractively valued, with a price/fair value ratio of 0.72 and a 4-star Morningstar rating, indicating it is undervalued by the market.

Sector peer Rio Tinto RIO also has a 0.72 price/fair value and a 4-star Morningstar rating. Both stocks have enjoyed lackluster share price performance, with Rio Tinto up just 3% during 2025 and Glencore down 8% over the same period. This is against an 18% rise in the Morningstar UK Index so far this year.

Rio can still close this valuation gap, Morningstar equity analyst Jon Mills said in a July note.

“Rio Tinto has low operating costs and a strong balance sheet, with capital allocation significantly improved following a period of overinvestment through the China commodities boom.

“However, it still faces the cyclicality of commodity prices, operating leverage, high capital intensity, and the risk of poor capital allocation.”

Are UK Housing Stocks a Buy?

Real estate stocks also appear cheaper than the overall UK market. An important contributor to the health of the UK economy, housebuilders have had a rough time after fresh promises of housing expansion by the new Labour government last year gave way to pessimism about the slow speed of interest rate cuts. Declining consumer confidence and prohibitive stamp duty increases have also poured water on recovery hopes. Those looking to buy or sell a property will also be anxiously awaiting the Autumn Budget in November, where proposed changes to the tax treatment of the sector are under consideration.

Key stocks Persimmon PSN, Barratt Redrow BTRW, and Taylor Wimpey TW. are all significantly undervalued. Overall, UK real estate companies are trading at around 0.85 price/fair value—a greater discount than the broader market. Investors will have to wait for the Autumn Budget on Nov. 26 to see whether there are any housing policies conducive to a more supportive environment for stocks.

In a recent report on UK homebuilders, Morningstar analyst Jack Fletcher-Price noted the depressed sector valuations, even after fair value estimates were cut in the summer.

“We lowered our fair value estimates for all homebuilders in the second quarter of 2025 after moderating our near- and medium-term expectations for house price growth and margin recovery, but they continue to screen attractively,” he said in September.

“Shares had performed reasonably well year-to-date, before the sector sold off once more as rate cut expectations were pared back and government bond yields rose.”

UK Healthcare Stocks in Focus

Among the UK’s discounted sectors, healthcare stocks are likewise attractively priced. Among the most attractive is GSK GSK, the British pharmaceutical manufacturer and research giant.

Morningstar senior equity analyst Jay Lee says the company’s broad range of innovative products help earn it a wide economic moat, suggesting it will be able to fend off competition in the healthcare sector for years—and potentially decades—to come. Its decision to divest of consumer business Haleon in 2022 also looks like a good long-term call, he says. The company has recently announced that chief executive Emma Walmsley will step down at the end of this year.

“GSK has shifted from its historical strategy of targeting slight enhancements toward true innovation,” Lee says.

“Also, it is focusing more on oncology and immunology, with genetic data to help develop the next generation of drugs. The benefits of these strategies are showing up in GSK’s early-stage drugs. We expect this focus will improve approval rates and pricing power. In contrast to respiratory drugs, treatments for cancer indications carry much stronger pricing power with payers.”

James Gard contributed to this story

The author or authors do not own shares in any securities mentioned in this article. Find out about
Morningstar’s editorial policies.